Heart and Stroke Foundation of Canada/Pfizer Research Fellowship - Chakrabarti


Dr. Subhadeep Chakrabarti
University of Alberta

Diabetes can decrease estrogen’s beneficial effects on blood vessels. The cells in the blood vessel walls of someone with diabetes can become resistant to the biochemical action of this hormone and become more vulnerable to conditions such as atherosclerosis – the formation of fatty deposits that impair blood flow and set the stage for a heart attack or stroke.
 
Dr. Subhadeep Chakrabarti, a post-doctoral fellow at the University of Alberta, is investigating whether some established diabetes medications can address this problem.
 
Dr. Chakrabarti, whose work is supervised by Dr. Sandra Davidge, is examining the possibility that pharmaceutical agents that reduce the levels of sugars might reverse the related damage caused to blood vessels. This would also reduce the risk of atherosclerosis.
 
Using samples of the cells that line veins and arteries, this research will study how estrogen transmits biochemical signals. By subjecting those cells to the same conditions that high blood sugars would cause in the body, Dr. Chakrabarti will look specifically at any interference with these signals, as well as how the medications’ activators might overcome that interference.
 
Dr. Chakrabarti’s work could help identify how existing diabetes medications might also be used to deal with cardiovascular challenges resulting from diabetes.
 
Supported by Pfizer Canada

 

English